April 28, 2015 / 1:02 PM / 2 years ago

BUZZ-Aeterna Zentaris Inc: Data Safety Monitoring Board recommends continuing late-stage trial

** Drug developer’s U.S.-listed shares up 10.3 pct at $0.64 premarket

** Independent Data Safety Monitoring Board recommended Friday late-stage trial of company’s experimental drug to treat type of cancer continue as planned

** Recommendation follows interim analysis of drug, zoptarelin doxorubicin, used to treat cancer arising from uterus lining

** Up to Monday’s close, stock gained 82.3 pct this year

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below